Afuco™ Anti-Human CD55 ADCC Therapeutic Antibody (PAT-SC1), ADCC Enhanced
Anti-CD55 ADCC Enhanced Antibody (PAT-SC1) is an ADCC enhanced antibody produced by our Afuco™ platform. PAT-SC1 has a strong potential to be used as an additive therapeutic agent in the treatment of patients with gastric cancers. A study conducted between 1997 and 2001, a single 20mg dose of PAT-SC1 administered before gastric resection surgery induced cell killing in human primary gastric tumours. This led to tumour cell regression in over half of PAT-SC1-treated patients. In the 10 year follow-up study of patients that participated in the trial, survival is significantly higher for PAT-SC1 treated patients as compared to an historical control group of patients that underwent a gastric resection but were not treated with PAT-SC1.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-126CL |
| Pricing | Inquiry |
| Host | Human |
| Target | CD55 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | 4 °C, -20°C if preferred |